Tokyo, April 3 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061141) titled 'A study on blood component measurements after consumption of the test food' on April 2.

Study Type: Interventional

Study Design: Basic Design - Cross-over Randomization - Randomized Blinding - Double blind -all involved are blinded Control - Active

Primary Sponsor: Institute - Life Science Division Fuji Chemical Industries Co., Ltd.

Condition: Condition - Healthy Japanese Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - To verify the time-dependent changes in blood astaxanthin compounds after consumption of the test food. Basic objectives2 - Others

Intervention: Interventions/Control_1 - Single ingestion

Test 1: Test food 1 Test 2: Test food 2

*The intervention sequence is Test 1 followed by Test 2. *The washout period is at least one week. Interventions/Control_2 - Single ingestion

Test 1: Test food 2 Test 2: Test food 1

*The intervention sequence is test 1 followed by test 2. *The washout period is at least one week.

Eligibility: Age-lower limit - 18 years-old =18.5 kg/m2 and <25 kg/m2 Key exclusion criteria - 1. Individuals who are receiving treatment for or have a history of malignant tumors, heart failure, or myocardial infarction

2. Individuals who have an implanted pacemaker or implantable cardioverter defibrillator

3. Individuals who are currently receiving treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, chronic kidney disease, cerebrovascular disease, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic disease

4. Individuals who consume Foods for Specified Health Uses or Foods with Functional Claims

5. Individuals who are taking or using medications (including herbal medicines) or supplements

6. Individuals who are allergic to medications or foods related to the test food

7. Individuals who are pregnant, lactating, or planning pregnancy during this study

8. Individuals who have participated in other clinical studies within 28 days before informed consent, or plan to participate in another study during this study

9. Individuals who have pre-existing gastrointestinal diseases (irritable bowel syndrome, inflammatory bowel disease, gastric ulcer, or gastroesophageal reflux disease)

10. Individuals who are deemed unsuitable for participation in this study by the principal investigator Target Size - 9

Recruitment Status: Recruitment status - Open public recruiting Date of protocol fixation - 2026 Year 03 Month 11 Day Date of IRB - 2026 Year 03 Month 11 Day Anticipated trial start date - 2026 Year 04 Month 02 Day Last follow-up date - 2026 Year 06 Month 20 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069962

Disclaimer: Curated by HT Syndication.